Skip to main content
Top

Open Access 15-04-2024 | Myocardial Infarction | Original Paper

Prevalence of elevated lipoprotein(a) in cardiac rehabilitation patients — results from a large-scale multicentre registry in Germany

Authors: Christoph Altmann, Nelu-Adrian Burlacu, Thomas Preuss, Annett Hlousek, Stephan Eddicks, on behalf of the MEDIAN Medical Board Cardiology

Published in: Clinical Research in Cardiology

Login to get access

Abstract

Background

Lipoprotein(a) (Lp(a)) is an independent risk factor for myocardial infarction and aortic valve stenosis. European guidelines recommend assessing it at least once in a lifetime, particularly in premature atherosclerotic heart disease.

Methods

A non-interventional registry was conducted at MEDIAN rehabilitation facilities in Germany to assess the frequency of Lp(a) testing in referring acute care hospitals and the prevalence of elevated Lp(a) levels in aortic valve stenosis or premature myocardial infarction. All consecutive patients referred after coronary intervention or aortic valve surgery were included in four cohorts: aortic valve intervention (cohort 1), current/previous myocardial infarction at < 60 years of age (cohorts 2a/2b), and myocardial infarction at ≥ 60 years of age (control).

Results

The analysis included 3393 patient records (cohort 1, n = 1063; cohort 2a, n = 1351; cohort 2b, n = 381; control, n = 598). Lp(a) had been determined at the referring hospital in 0.19% (cohort 1), 4.96% (cohort 2a), 2.36% (cohort 2b), and 2.01% (control) of patients. Lp(a) levels were > 50 mg/dL or > 125 nmol/L in 28.79% (cohort 1), 29.90% (cohort 2a), and 36.48% (cohort 2b; p < 0.001) compared to 24.25% (control). Family history of premature cardiovascular disease was reported in 13.45% (cohort 1), 38.56% (cohort 2a), and 32.81% (cohort 2b) compared to 17.89% (control; p < 0.05 for each comparison).

Conclusions

Lp(a) had been rarely assessed in acute management of aortic valve stenosis or premature myocardial infarction despite expanding scientific evidence and guideline recommendation. Given the above-average incidence of elevated Lp(a) levels, awareness for Lp(a) has to increase substantially to better identify and manage high-risk patients.

Graphical Abstract

Literature
1.
go back to reference Wienbergen H, Boakye D, Günther K, Schmucker J, Mata Marín LA, Kerniss H et al (2022) Lifestyle and metabolic risk factors in patients with early-onset myocardial infarction: a case-control study. Eur J Prev Cardiol 29(16):2076–2087CrossRefPubMed Wienbergen H, Boakye D, Günther K, Schmucker J, Mata Marín LA, Kerniss H et al (2022) Lifestyle and metabolic risk factors in patients with early-onset myocardial infarction: a case-control study. Eur J Prev Cardiol 29(16):2076–2087CrossRefPubMed
2.
go back to reference Fach A, Bünger S, Zabrocki R, Schmucker J, Conradi P, Garstka D et al (2015) Comparison of outcomes of patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention analyzed by age groups (<75, 75 to 85, and >85 Years); (Results from the Bremen STEMI Registry). Am J Cardiol 116(12):1802–1809CrossRefPubMed Fach A, Bünger S, Zabrocki R, Schmucker J, Conradi P, Garstka D et al (2015) Comparison of outcomes of patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention analyzed by age groups (<75, 75 to 85, and >85 Years); (Results from the Bremen STEMI Registry). Am J Cardiol 116(12):1802–1809CrossRefPubMed
3.
go back to reference Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L et al (2022) Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 43(39):3925–3946CrossRefPubMedPubMedCentral Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L et al (2022) Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 43(39):3925–3946CrossRefPubMedPubMedCentral
4.
go back to reference Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG (2008) Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 117(2):176–184CrossRefPubMed Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG (2008) Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 117(2):176–184CrossRefPubMed
5.
go back to reference Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG (2014) Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol 63(5):470–477CrossRefPubMed Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG (2014) Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol 63(5):470–477CrossRefPubMed
6.
go back to reference Paré G, Çaku A, McQueen M, Anand SS, Enas E, Clarke R et al (2019) Lipoprotein(a) Levels and the risk of myocardial infarction among 7 ethnic groups. Circulation 139(12):1472–1482CrossRefPubMed Paré G, Çaku A, McQueen M, Anand SS, Enas E, Clarke R et al (2019) Lipoprotein(a) Levels and the risk of myocardial infarction among 7 ethnic groups. Circulation 139(12):1472–1482CrossRefPubMed
7.
go back to reference Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al (2020) 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41(1):111–188CrossRefPubMed Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al (2020) 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41(1):111–188CrossRefPubMed
8.
go back to reference Grundy Scott M, Stone Neil J, Bailey Alison L, Beam C, Birtcher Kim K, Blumenthal Roger S et al (2019) 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA GUIDELINE on the management of blood cholesterol: executive summary. J Am Coll Cardiol 73(24):3168–3209CrossRefPubMed Grundy Scott M, Stone Neil J, Bailey Alison L, Beam C, Birtcher Kim K, Blumenthal Roger S et al (2019) 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA GUIDELINE on the management of blood cholesterol: executive summary. J Am Coll Cardiol 73(24):3168–3209CrossRefPubMed
9.
go back to reference Stürzebecher PE, Schorr JJ, Klebs SHG, Laufs U (2023) Trends and consequences of lipoprotein(a) testing: cross-sectional and longitudinal health insurance claims database analyses. Atherosclerosis 367:24–33CrossRefPubMed Stürzebecher PE, Schorr JJ, Klebs SHG, Laufs U (2023) Trends and consequences of lipoprotein(a) testing: cross-sectional and longitudinal health insurance claims database analyses. Atherosclerosis 367:24–33CrossRefPubMed
10.
go back to reference Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF et al (2010) Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 31(23):2844–2853CrossRefPubMedPubMedCentral Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF et al (2010) Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 31(23):2844–2853CrossRefPubMedPubMedCentral
11.
go back to reference van Buuren F, Horstkotte D, Knabbe C, Hinse D, Mellwig KP (2017) Incidence of elevated lipoprotein (a) levels in a large cohort of patients with cardiovascular disease. Clin Res Cardiol Suppl 12(Suppl 1):55–59CrossRefPubMedPubMedCentral van Buuren F, Horstkotte D, Knabbe C, Hinse D, Mellwig KP (2017) Incidence of elevated lipoprotein (a) levels in a large cohort of patients with cardiovascular disease. Clin Res Cardiol Suppl 12(Suppl 1):55–59CrossRefPubMedPubMedCentral
12.
go back to reference Allahyari A, Jernberg T, Hagstrom E, Leosdottir M, Lundman P, Ueda P (2020) Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study. Eur Heart J 41(40):3900–3909CrossRefPubMedPubMedCentral Allahyari A, Jernberg T, Hagstrom E, Leosdottir M, Lundman P, Ueda P (2020) Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study. Eur Heart J 41(40):3900–3909CrossRefPubMedPubMedCentral
13.
go back to reference Makhmudova U, Samadifar B, Maloku A, Haxhikadrija P, Geiling JA, Romer R et al (2023) Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction (“Jena auf Ziel”). Clin Res Cardiol 112(9):1212–1219CrossRefPubMedPubMedCentral Makhmudova U, Samadifar B, Maloku A, Haxhikadrija P, Geiling JA, Romer R et al (2023) Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction (“Jena auf Ziel”). Clin Res Cardiol 112(9):1212–1219CrossRefPubMedPubMedCentral
14.
15.
go back to reference Reeskamp LF, Tromp TR, Patel AP, Ibrahim S, Trinder M, Haidermota S et al (2023) Concordance of a high lipoprotein(a) concentration among relatives. JAMA Cardiology 8(12):1111–1118CrossRefPubMed Reeskamp LF, Tromp TR, Patel AP, Ibrahim S, Trinder M, Haidermota S et al (2023) Concordance of a high lipoprotein(a) concentration among relatives. JAMA Cardiology 8(12):1111–1118CrossRefPubMed
17.
go back to reference Szarek M, Reijnders E, Jukema JW, Bhatt DL, Bittner VA, Diaz R et al (2024) Relating lipoprotein(a) concentrations to cardiovascular event risk after acute coronary syndrome: a comparison of three tests. Circulation 149(3):192–203CrossRefPubMed Szarek M, Reijnders E, Jukema JW, Bhatt DL, Bittner VA, Diaz R et al (2024) Relating lipoprotein(a) concentrations to cardiovascular event risk after acute coronary syndrome: a comparison of three tests. Circulation 149(3):192–203CrossRefPubMed
18.
go back to reference Gaede L, Blumenstein J, Husser O, Liebetrau C, Dörr O, Grothusen C et al (2021) Aortic valve replacement in Germany in 2019. Clin Res Cardiol 110(3):460–465CrossRefPubMed Gaede L, Blumenstein J, Husser O, Liebetrau C, Dörr O, Grothusen C et al (2021) Aortic valve replacement in Germany in 2019. Clin Res Cardiol 110(3):460–465CrossRefPubMed
19.
go back to reference Freisinger E, Fuerstenberg T, Malyar NM, Wellmann J, Keil U, Breithardt G et al (2014) German nationwide data on current trends and management of acute myocardial infarction: discrepancies between trials and real-life. Eur Heart J 35(15):979–988CrossRefPubMed Freisinger E, Fuerstenberg T, Malyar NM, Wellmann J, Keil U, Breithardt G et al (2014) German nationwide data on current trends and management of acute myocardial infarction: discrepancies between trials and real-life. Eur Heart J 35(15):979–988CrossRefPubMed
Metadata
Title
Prevalence of elevated lipoprotein(a) in cardiac rehabilitation patients — results from a large-scale multicentre registry in Germany
Authors
Christoph Altmann
Nelu-Adrian Burlacu
Thomas Preuss
Annett Hlousek
Stephan Eddicks
on behalf of the MEDIAN Medical Board Cardiology
Publication date
15-04-2024
Publisher
Springer Berlin Heidelberg
Published in
Clinical Research in Cardiology
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-024-02427-0